Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients
| العنوان: | Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients |
|---|---|
| المؤلفون: | Karin Tarte, Thomas E. Witzig, Imane Azzaoui, Thomas M. Habermann, Andrew L. Feldman, Céline Pangault, Noel Milpied, Stephen M. Ansell, Thierry Fest, Marie Parrens, Matthew J. Maurer, James R. Cerhan, Delphine Rossille, Mikael Roussel, Susan L. Slager, Thierry Lamy, Gaëlle Labouré, Brian K. Link |
| المساهمون: | Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], Mayo Clinic [Rochester], CHU Bordeaux [Bordeaux], University of Iowa [Iowa City], This study is supported by the French Health Minister (BMS_LyTrans project, NCT01287923), the National Institute of Cancer (INCa Translational Research 2010), the French Lymphoma Study Association (LYSA), the French National Agency for Research (ANR Carnot/CALYM), the National Cancer Institute (P50 CA97274, R01 CA92153), and the Henry J Predolin Foundation. Concerning the French cohort, we are indebted to the LYSA pathology platform (Hôpital Henri Mondor, Créteil) for immunohistochemical experiments, the Centre de Ressources Biologiques CRB-Santé (BB-0033-00056) of the Rennes hospital for providing high quality samples. This work was partly supported by a French National Cancer Institute post-doctoral fellowship (grant number PDOC-RC-GO/07-003) to the first author (D.R.)., Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Chard-Hutchinson, Xavier |
| المصدر: | Leukemia Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2017, 31 (4), pp.988-991. ⟨10.1038/leu.2016.385⟩ Leukemia, 2017, 31 (4), pp.988-991. ⟨10.1038/leu.2016.385⟩ |
| بيانات النشر: | Springer Science and Business Media LLC, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Adult, Male, [SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Cancer Research, medicine.medical_specialty, Adolescent, Programmed Cell Death 1 Receptor, [SDV.CAN]Life Sciences [q-bio]/Cancer, Article, Young Adult, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Refractory, immune system diseases, hemic and lymphatic diseases, Internal medicine, Biomarkers, Tumor, Tumor Microenvironment, medicine, Humans, ComputingMilieux_MISCELLANEOUS, Aged, Aged, 80 and over, Hematology, business.industry, Peripheral tolerance, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Middle Aged, Prognosis, medicine.disease, 3. Good health, Lymphoma, Leukemia, Oncology, Apoptosis, 030220 oncology & carcinogenesis, Immunology, Cancer research, Female, Rituximab, Lymphoma, Large B-Cell, Diffuse, business, Diffuse large B-cell lymphoma, 030215 immunology, medicine.drug |
| الوصف: | Diffuse large B-cell lymphoma (DLBCL) is an aggressive hematologic malignancy with more than two-thirds of the patients cured with first-line rituximab-based treatments. However, relapsing or refractory patients have a very poor survival despite salvage therapies. The PD-1/PD-L1 pathway plays a major role in peripheral tolerance and homeostasis by inhibiting T-cell activation. |
| وصف الملف: | application/pdf |
| تدمد: | 1476-5551 0887-6924 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a0877267aca814536e5a4718fd95531Test https://doi.org/10.1038/leu.2016.385Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....5a0877267aca814536e5a4718fd95531 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14765551 08876924 |
|---|